HN2010000573A - Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, metodos y usos - Google Patents
Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, metodos y usosInfo
- Publication number
- HN2010000573A HN2010000573A HN2010000573A HN2010000573A HN2010000573A HN 2010000573 A HN2010000573 A HN 2010000573A HN 2010000573 A HN2010000573 A HN 2010000573A HN 2010000573 A HN2010000573 A HN 2010000573A HN 2010000573 A HN2010000573 A HN 2010000573A
- Authority
- HN
- Honduras
- Prior art keywords
- methods
- compositions
- epithopes
- formulations
- bodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
LA PRESENTE INVENCION A UN ANTICUERPO ANTI-IL-12/23P40 QUE SE UNE A UNA PORCION DE LA PROTEINA IL-12 O IL-23 QUE CORRESPONDE A LA SUBUNIDAD P40 DE IL-12 O IL-23, QUE INCLUYEN COMPOSICIONES, FORMULAS Y METODOS DE ADMINISTRACION CON APLICACIONES EN DIAGNOSTICO Y/O USOS Y DISPOSITIVOS TERAPEUTICOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97599707P | 2007-09-28 | 2007-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
HN2010000573A true HN2010000573A (es) | 2012-12-10 |
Family
ID=40850818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HN2010000573A HN2010000573A (es) | 2007-09-28 | 2010-03-26 | Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, metodos y usos |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090181027A1 (es) |
EP (1) | EP2205276A4 (es) |
CR (1) | CR11399A (es) |
EC (1) | ECSP10010056A (es) |
GT (1) | GT201000073A (es) |
HN (1) | HN2010000573A (es) |
NI (1) | NI201000042A (es) |
SV (1) | SV2010003517A (es) |
WO (1) | WO2009114040A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014506132A (ja) * | 2011-01-07 | 2014-03-13 | アッヴィ・インコーポレイテッド | 抗il−12/il−23抗体およびその使用 |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
US20180094052A1 (en) * | 2016-09-30 | 2018-04-05 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody |
KR20190129061A (ko) | 2017-03-31 | 2019-11-19 | 메이지 세이카 파루마 가부시키가이샤 | 수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
WO2019106206A1 (en) * | 2017-12-01 | 2019-06-06 | Fyb 202 Project Gmbh | Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody |
US11578124B2 (en) | 2018-05-18 | 2023-02-14 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-IL12/IL23 antibody |
FI3883606T3 (fi) | 2018-09-24 | 2023-09-07 | Janssen Biotech Inc | Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella |
BR112021009287A2 (pt) | 2018-11-20 | 2021-10-26 | Janssen Biotech, Inc. | Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23 |
AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
MX2022001305A (es) * | 2019-07-30 | 2022-05-06 | Akeso Biopharma Inc | Anticuerpo de dominio proteínico p40 anti-humana y uso del mismo. |
CA3170677A1 (en) * | 2020-02-14 | 2021-08-19 | Janssen Biotech, Inc. | Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
TR200603997T1 (tr) * | 1999-03-25 | 2010-01-21 | Abbott Gmbh & Co. Kg | Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler. |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
ES2644275T3 (es) * | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
EA016022B1 (ru) * | 2004-12-21 | 2012-01-30 | Сентокор, Инк. | Выделенное антитело млекопитающего против il-12 и способ изменения его активности |
US20090110681A1 (en) * | 2005-03-08 | 2009-04-30 | Pfizer, Inc. | Anti-M-CSF Antibody Compositions |
AU2006259536A1 (en) * | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-IGF1R antibody formulations |
EP1893647A2 (en) * | 2005-06-23 | 2008-03-05 | MedImmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
EP1977763A4 (en) * | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
-
2008
- 2008-09-26 EP EP08873207A patent/EP2205276A4/en not_active Withdrawn
- 2008-09-26 US US12/238,804 patent/US20090181027A1/en not_active Abandoned
- 2008-09-26 WO PCT/US2008/077839 patent/WO2009114040A2/en active Application Filing
-
2010
- 2010-03-25 NI NI201000042A patent/NI201000042A/es unknown
- 2010-03-26 SV SV2010003517A patent/SV2010003517A/es unknown
- 2010-03-26 HN HN2010000573A patent/HN2010000573A/es unknown
- 2010-03-26 GT GT201000073A patent/GT201000073A/es unknown
- 2010-03-26 EC EC2010010056A patent/ECSP10010056A/es unknown
- 2010-04-28 CR CR11399A patent/CR11399A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2205276A4 (en) | 2012-08-15 |
US20090181027A1 (en) | 2009-07-16 |
SV2010003517A (es) | 2010-08-10 |
GT201000073A (es) | 2012-04-19 |
CR11399A (es) | 2010-08-18 |
EP2205276A2 (en) | 2010-07-14 |
WO2009114040A3 (en) | 2010-05-27 |
WO2009114040A2 (en) | 2009-09-17 |
NI201000042A (es) | 2010-09-13 |
ECSP10010056A (es) | 2010-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HN2010000573A (es) | Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, metodos y usos | |
EA200870129A1 (ru) | Человеческие антитела против il-23, композиции, способы и применение | |
AR060130A1 (es) | Formulacion de un anticuerpo monoclonal humano anti- igf-1r | |
ECSP077261A (es) | Composición de anticuerpo her2 | |
EA200900040A1 (ru) | Молекулы антител, которые связываются с человеческим il-17 | |
AR051484A1 (es) | Moleculas de anticuerpo que tienen especificidad para la il - 17 humana | |
HN2006016512A (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
CR20160203A (es) | Inhibidores de tirosina cinasa de bruton | |
UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн | |
CY1116842T1 (el) | Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου | |
CY1114690T1 (el) | Αντισωματα αντι-nrr notch1 και μεθοδοι χρησεις αυτων | |
CY1112277T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
CY1121895T1 (el) | Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19 | |
CR10561A (es) | Vacunas para malaria | |
CL2008003537A1 (es) | Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor. | |
BR112015023391A8 (pt) | formulações de conjugados anticorpo-droga anti-egfr | |
EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
MY157772A (en) | Antibody formulation | |
EA200702616A1 (ru) | Дозированная форма для перорального применения | |
MX2009005414A (es) | Formulaciones liquidas de anticuerpo antirrabico. | |
CY1113869T1 (el) | Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf | |
BRPI0416141A (pt) | anticorpo anti-cd52 modificado |